Exentis Group
Swiss pioneer of patented Additive Screen Printing technology enabling mass production of millions of precision micro-structured components (125 µm channel resolution) in metals, ceramics, polymers, and pharmaceutical materials on a single industrial platform — addressing the gap between conventional AM (low-volume) and traditional manufacturing (no geometric freedom).
- CEO / Founder
- Dr. Rolf Bachmann
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- CHF 15M
Technology & Products
Key Products
Exentis 3D Production Systems (industrial variant); Exentis Pharma cleanroom production systems (tablets with adjustable drug release profiles); Contract manufacturing services (AMaaS model); Application-specific licenses for exclusive customer verticals; Material pastes (metals, ceramics, polymers, pharma APIs, biomaterials); Part development project services
Technological Advantage
CLAIMED: 'world's only' industrialized AM technology for mass production at millions-of-parts scale; 125 µm channel resolution in metals and ceramics; multi-material processing (metals, ceramics, polymers, pharma) on one platform; 48-hour screen changeover for rapid geometry changes. VERIFIED: patents secured across critical aspects of 3D screen printing process (specific patent numbers not publicly disclosed in available sources); commercially validated at scale — CHF 14.1M H1 2024 revenue (+24% YoY), 23% EBITDA margin, $22.4M in US production system sales (Q4 2024); major 10-system order secured; pharmaceutical cleanroom system installed at Italian customer. DEFENSIBLE: patented process with application-specific exclusive licensing creates customer lock-in. REPLICABLE RISK: screen printing is a known industrial process; depth and breadth of patent portfolio determines true defensibility.
Differentiation
Value Proposition
Enables industrial and pharmaceutical OEMs to mass-produce millions of micro-structured components with 125 µm channel widths — geometries impossible with conventional AM — at production economics validated by CHF 14.1M H1 2024 revenue (+24% YoY) and 23% EBITDA margin; $22.4M in US production system sales (2024) confirms global demand; cold paste printing process eliminates material waste and allows geometry changes within 48 hours via new screen tooling.
How They Differentiate
Unlike Lithoz (ceramic-only DLP/LCM, limited to ceramics, batch production) and Desktop Metal/ExOne (single-material binder jetting, sintering-dependent accuracy), Exentis processes metals, ceramics, polymers, and pharma APIs on one unified platform; achieves 125 µm channel resolution at true mass-production volumes (millions of parts per year) vs. typical AM runs of 1–10,000 units; cold paste process avoids sintering shrinkage and distortion that limits binder jetting dimensional accuracy; 48-hour screen changeover for geometry changes enables mass customization at zero tooling lead time vs. weeks for metal injection molding or casting tooling; application-exclusive licensing model creates defensible customer relationships not available through equipment-only competitors.
Market & Competition
Target Customers
Industrial OEMs requiring mass production of micro-structured metal or ceramic components (hydraulic micro-filters, cooling channels, precision parts); pharmaceutical manufacturers needing high-volume tablets with freely adjustable drug release profiles; electronics, automotive, and medical device companies requiring fine-feature components at millions-of-parts scale
Industry Verticals
Industrial Manufacturing; Pharmaceuticals; Medical Devices; Electronics; Automotive; Aerospace
Competitors
Lithoz (high-precision ceramic AM systems for industrial production, LCM/DLP technology); Desktop Metal / ExOne (binder jetting for high-volume metal and ceramic component production at industrial scale)
Growth & Milestones
Growth Metrics
H1 2024 revenue: CHF 14.1M (+24% YoY); H1 2024 EBITDA margin: 23% (profitable at scale); US market 2024: $22.4M in production system sales; Q4 2024: 9 production systems sold to US customers; Major order secured for 10 additional production systems; US pipeline of ongoing projects expected to yield further development contracts, manufacturing orders, and purchase agreements; expanding from primarily European operations to global platform with US subsidiary established 2023
Major Milestones
Patented 3D screen printing (Additive Screen Printing) technology developed and commercialized; Exentis Pharma cleanroom production systems launched; 2023: Founded Exentis North America Inc. (US expansion); H1 2024: CHF 14.1M revenues (+24% YoY), EBITDA margin 23%; Q4 2024: Sold 9 Exentis production systems to US customers; 2024: Total US machine sales reached $22.4M across multiple customers; Secured major order for 10 additional production systems (large-scale industrial applications); Laxxon Medical–Hovione long-term pharmaceutical strategic cooperation announced; Restructured management with dedicated CCO (Michael Leitner) and CPO (Dr. Srdan Vasic) to accelerate market penetration; AGM 2024 attended by 120 shareholders
Notable Customers
Unnamed Italian pharmaceutical company (Exentis Pharma cleanroom production system installed for tablets with adjustable release profiles); multiple unnamed US industrial customers (9 production systems purchased Q4 2024; $22.4M in total US machine sales 2024)